Format

Send to

Choose Destination
Eur J Pharm Sci. 2019 Mar 7;132:118-120. doi: 10.1016/j.ejps.2019.02.027. [Epub ahead of print]

Promoting cannabis products to pharmaceutical drugs.

Author information

1
Institute of Plant Science, Agriculture Research Organization, Volcani Center, Rishon LeZion 7528809, Israel. Electronic address: hkoltai@agri.gov.il.
2
Consultant Patrick Poulin Inc., Québec City, Québec, Canada; School of Public Health, Université de Montréal, Montréal, Canada.
3
Institute of Plant Science, Agriculture Research Organization, Volcani Center, Rishon LeZion 7528809, Israel.

Abstract

Cannabis sativa is widely used for medical purposes. However, to date, aroma, popular strain name or the content of two phytocannabinoids-Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are mostly considered for therapeutic activity. This is despite the hundreds of compounds in this plant and their potential synergistic interactions in mixtures. New, specific and effective cannabis-based drugs must be developed to achieve adequate medical standards for the use of cannabis. To do this, the comprehensive molecular profile of cannabis-based drugs must be defined, and mixtures of compounds should be tested for superior therapeutic activity due to synergistic effects compared to individually isolated cannabis compounds. The biological pathways targeted by these new drugs should also be characterized more accurately. For drug development and design, absorption, distribution, metabolism and elimination versus toxicity (ADME/Tox) must be characterized, and therapeutic doses identified. Promoting the quality and therapeutic activity of herbal or synthetic cannabis products to pharma grade is a pressing need worldwide.

KEYWORDS:

Cannabinoid; Cannabis sativa; Drug development; First-in-human; Synergy; Terpene

PMID:
30851400
DOI:
10.1016/j.ejps.2019.02.027

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center